Drug Profile
Research programme: growth factor peptides - NephRx Corporation
Alternative Names: NX 002Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator NephRx Corporation
- Class Growth factors; Peptides
- Mechanism of Action Growth factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammatory bowel diseases; Stomatitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Stomatitis in USA (Parenteral)
- 11 Nov 2010 NephRx Corporation receives Qualifying Therapeutic Discovery Project grant under the Patient Protection and Affordable Care Act of 2010 (PPACA)